A Discussion on Clinical Strategies for Treating Aggressive Non-Hodgkin Lymphoma (NHL) (Nurse)

Credit Available: CABRN, CME, ILNA

 

Enroll in this Course

FREE

access until April 28, 2028 12:00 am

Enroll Now

Activity Description

The recorded webinar will provide the opportunity for HCPs to expand their knowledge about treating non-Hodgkin lymphoma with chemoimmunotherapies, autologous transplant, and novel therapies, including CART-cell and bispecific therapies. The webinar will focus on management of patients receiving active treatment, monitoring for long-term and late effects of treatment, role of clinical trials, and the roles of the healthcare team members needed when treating patients. It will include information about approved therapies and those in clinical trials.

Time to Complete Activity: 1.0 hours

This course is available from:

October 27, 2026 until April 28, 2028

Course Instructors

Joshua Brody, MD Speaker

Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai Hess Center for Science and Medicine, New York, New York

Katie Gettinger, MSN, RN, CPNP-PC, CPHON Speaker

Clinical Trial Nurse Navigator, Clinical Trial Support Center, Blood Cancer United, Washington, DC

Target Audience

This activity is intended for hematologists-oncologists, medical oncologists, NPs, nurses, and other healthcare professionals engaged in the care of patients with Non-Hodgkin Lymphoma (NHL).

Learning Objectives
After completing this activity, the participant should be better able to:

• • Explain treatment options focusing on latest developments and new therapies for patients with aggressive NHL, such as DLBCL
  • Interpret the clinical significance of new and emerging data on therapies such as antibody-drug conjugates, bispecific antibodies, and CAR-T
  • Identify patients who are candidates for newly approved therapies
  • Explain the HCP’s role in preparing the patient for therapy, administering treatment, monitoring for and managing side effects
  • Identify resources to support patients and their caregivers

Accreditation, Credit and Support

In support of improving patient care, this activity has been planned and implemented by Blood Cancer United and Medical Learning Institute Inc.  Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.   Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Registered Nursing Credit Designation

Approval for nurses has been obtained by the National Office of Blood Cancer United under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.

ILNA Recertification Points

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: Care Continuum (OCN, CBCN, CPHON, AOCNP, ROCN) 0.25*, Foundations of Transplant/HSCT and Cellular Therapy (TCTCN) 0.5*, HSCT and Cellular Therapy Process and Administration (TCTCN) 0.25*, Post Cellular Therapy Management and Education (TCTCN) 0.25*, Quality of Life (TCTCN) 0.25*, Transplant Process and Infusion (TCTCN) 0.25*, Treatment (AOCNP, CBCN, CPHON, OCN, ROCN) 0.5*.

Total points: 1.0

*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.

Providers

This activity is provided by Blood Cancer United and Medical Learning Institute Inc.

         

Support Statement

There is no commercial support associated with this CE activity.

Disclosure of Conflicts of Interest Policy

Blood Cancer United and Medical Learning Institute Inc, are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, Blood Cancer United and MLI require faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to Blood Cancer United and MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures

Joshua Brody, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: ADC Therapeutics, Corvus, Merck, Novartis, Pfizer
Research Funding/Support: AstraZeneca, BeOne, Bristol Myers Squibb, Genentech/Roche, Merck
Other: Contracted researcher: AstraZeneca, BeOne, Bristol Myers Squibb, Genentech/Roche, Merck

Katie Gettinger MSN, RN, CPNP-PC, CPHON, has no relevant financial relationships with ineligible companies to disclose for this educational activity

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Blood Cancer United and Medical Learning Institute Inc do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the accredited CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

About this Activity

Blood Cancer United and Medical Learning Institute Inc are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Blood Cancer United and Medical Learning Institute Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit.  You will receive your certificate from Medical Learning Institute Inc.

For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact Nicole Dane at ndane@mlieducation.org 

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at profeducation@bloodcancerunited.org.